China News Service, Beijing, September 28 (Reporter Li Shuangnan) Funded by the Chinese Committee of the International Society for Neurorehabilitation, and chaired by Professor Huang Hongyun, Honorary Director of the Institute of Neuroprosthetics, the Third Medical Center of the PLA General Hospital, "olfactory ensheathing cells treat ischemic The clinical trial of sequelae of stroke was officially completed, and the results were published online today in the official journal of the International Society for Neurorehabilitation and the Journal of Neuroprosthetics published by Tsinghua University Press.
Professor Huang Hongyun told reporters from China News Agency that this is a major breakthrough in China's research on cell therapy for stroke sequelae.
Professor Huang Hongyun introduced that this topic is the highest level of evidence-based medicine evidence in a multi-center, randomized, double-blind, placebo-controlled clinical trial study. The results show that the comparison of the olfactory ensheathing cell treatment control group and the placebo control group is There are significant differences in the evaluation of neurological function; there are also significant differences in the comparison between the end point and the starting function evaluation of the olfactory ensheathing cell treatment group; compared with the control group, the olfactory ensheathing cell treatment group is safe in treatment and the quality of life of patients has been significantly improved.
This is the first positive result report of the highest level of evidence-based medicine in clinical cell therapy for neurological diseases including stroke in the world so far.
Neurological disease cells (including various stem cells) have been explored in clinical treatment for more than twenty years. Although most results are reported as positive in non-double-blind controlled studies, there is no research with the highest level of evidence-based medical evidence. The report proves that it has a nerve repair effect.
The olfactory nerve is the only tissue in the nervous system that can regenerate and repair itself throughout the life. This important feature and ability mainly depends on the strong support of olfactory ensheathing cells, but a large number of olfactory ensheathing cells in vitro has always been a technical difficulty that cannot be overcome.
Professor Huang Hongyun’s team has worked hard for more than ten years, and obtained Chinese and American patents for the core technology of large-scale production of olfactory ensheathing cells. From cell source production to clinical treatment technology mastery and exploration, it stands at the forefront of neuroreparation clinical cell therapy. The original and innovative breakthrough in repairing the sequelae of nerve damage from 0 to 1.
Professor Huang Hongyun said that this major innovation will change the understanding and treatment model of stroke and neurological diseases, and provide achievable clinical technical support guarantee for Healthy China.
(Finish)